AR076372A1 - Derivados de etil-tiotriazol, composiciones farmaceuticas que los comprenden, intermediarios para su sintesis y su uso en el tratamiento de trastornos mediados por mglur5 - Google Patents

Derivados de etil-tiotriazol, composiciones farmaceuticas que los comprenden, intermediarios para su sintesis y su uso en el tratamiento de trastornos mediados por mglur5

Info

Publication number
AR076372A1
AR076372A1 ARP100101333A ARP100101333A AR076372A1 AR 076372 A1 AR076372 A1 AR 076372A1 AR P100101333 A ARP100101333 A AR P100101333A AR P100101333 A ARP100101333 A AR P100101333A AR 076372 A1 AR076372 A1 AR 076372A1
Authority
AR
Argentina
Prior art keywords
tolyl
ethyl
oxadiazol
tetrazol
pharmaceutical compositions
Prior art date
Application number
ARP100101333A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR076372A1 publication Critical patent/AR076372A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos derivados de etil-tio-triazol, a intermediarios para su preparacion, su uso en terapia y composiciones farmacéuticas que comprenden a estos compuestos. Reivindicacion 1: Un compuesto de formula (1) en donde R1 es metilo, halogeno o ciano; R2 es hidrogeno o fluoro; R3 es hidrogeno, alquilo C1-3 o ciclopropilo; R4 es hidrogeno, alquilo C1-3 o ciclopropilo; R5 es alquilo C1-C3 o ciclopropilo; X es como en formulas (2); Y es C o N; y Z es como en formulas (3) o una sal, hidrato, isoforma, tautomero o enantiomero farmacéuticamente aceptable de este. Reivindicacion 19: Un compuesto seleccionado de (E)-2-amino-2-(3-metilbenzoiloxiimino)acetato de etilo; 5-m-tolil-1,2,4-oxadiazol-3-carboxilato de etilo; 1-(2-m-tolil-2H-tetrazol-5-il)etanona; 1-(5-m-tolilisoxazol-3-il)etanona; 1-(5-m-tolil-1,2,4-oxadiazol-3-il)etanona; (S)-1-(5-m-tolilisoxazol-3-il)etanol; (S)-1-(5-m-tolil-1,2,4-oxadiazol-3-il)etanol; (S)-1-(2-m-tolil-2H-tetrazol-5-il)etanol; (S)-metanosulfonato de 1-(5-m-tolilisoxazol-3-il)etilo; (S)-metanosulfonato de 1-(2-m-tolil-2H-tetrazol-5-il)etilo; (S)-metanosulfonato de 1-(2-(3-clorofenil)-2H-tetrazol-5-il)etilo; (S)-metanosulfonato de 1-(5-m-tolil-1,2,4-oxadiazol-3-il)etilo; 4-(4-metil-5-tioxo-4,5-dihidro-1 H-1,2,4-triazol-3-il)piridin-2(1H)-ona; y 5-(4-metil-5-tioxo-4,5-dihidro-1H-1,2,4-triazol-3-il)piridazin-3(2H)-ona.
ARP100101333A 2009-04-23 2010-04-22 Derivados de etil-tiotriazol, composiciones farmaceuticas que los comprenden, intermediarios para su sintesis y su uso en el tratamiento de trastornos mediados por mglur5 AR076372A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17195009P 2009-04-23 2009-04-23

Publications (1)

Publication Number Publication Date
AR076372A1 true AR076372A1 (es) 2011-06-08

Family

ID=42992671

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101333A AR076372A1 (es) 2009-04-23 2010-04-22 Derivados de etil-tiotriazol, composiciones farmaceuticas que los comprenden, intermediarios para su sintesis y su uso en el tratamiento de trastornos mediados por mglur5

Country Status (5)

Country Link
US (1) US20100273805A1 (es)
AR (1) AR076372A1 (es)
TW (1) TW201041577A (es)
UY (1) UY32569A (es)
WO (1) WO2010123451A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737518A (en) * 1984-04-03 1988-04-12 Takeda Chemical Industries, Ltd. Lipid derivatives, their production and use
KR20070027504A (ko) * 2004-02-18 2007-03-09 아스트라제네카 아베 테트라졸 화합물 및 대사성 글루타메이트 수용체길항제로서 이들의 용도
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EA200601266A1 (ru) * 2004-02-18 2007-02-27 Астразенека Аб Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
TW200821305A (en) * 2006-10-05 2008-05-16 Astrazeneca Ab MGluR5 modulators
EP1921073A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole derivatives as sigma receptor inhibitors
EP2231621B1 (en) * 2008-01-08 2016-11-02 Merck Sharp & Dohme Corp. Process for preparing n-substituted hydroxypyrimidinone carboxamides
WO2009142732A2 (en) * 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
WO2010111058A1 (en) * 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain

Also Published As

Publication number Publication date
WO2010123451A1 (en) 2010-10-28
TW201041577A (en) 2010-12-01
UY32569A (es) 2010-11-30
US20100273805A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
RU2439068C2 (ru) Модуляторы mglur5
JP4294960B2 (ja) 抗癌剤としてのサイクリン依存性キナーゼ阻害剤
AR102487A1 (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
AR075238A1 (es) Compuestos de piridazinona
AR061567A1 (es) Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos
PE20060121A1 (es) Compuestos amidas biciclicos como antagonistas del receptor de acetilcolina muscarinico m3
JP2007507542A5 (es)
PE20160521A1 (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida
JP2015172062A5 (es)
ATE480239T1 (de) Angiogeneseinhibitoren
NZ595553A (en) VINYL INDAZOLYL COMPOUND; (E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol
PE20081704A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
RU2011139893A (ru) Фунгицидные пиразолы
PE20061038A1 (es) Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion
JP2012519693A5 (es)
AR060651A1 (es) Derivados de 1,2,4-triazol como moduladores de mglur5 i, intermediarios para su sintesis, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del dolor y de trastornos gastrointestinales
AR080754A1 (es) Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
RU2012134306A (ru) Азотосодержащие производные гетероарилов
MX2012002534A (es) Derivados de (tio) morfolina como moduladores de esfingosin-1-fosfato.
AR068921A1 (es) Derivados heterociclicos de tetrazol y 1,2-4 triazoles, composiciones farmaceuticas que los contienen y usos de los mismos para tratar desordenes neurologicos, gastrointestinales y del dolor,entre otros.
JP2010502576A5 (es)
JP2015524483A5 (es)
JP2016520635A5 (es)
JP2017500321A5 (es)
JP2017519818A5 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure